Hepion Pharmaceuticals (NASDAQ:HEPA) released a video illustrating CRV431’s mechanism of action in non-alcoholic steatohepatitis (NASH).
CRV431 inhibits multiple forms of cyclophilins to impact multiple stages of NASH. In addition to targeting liver cell death and inflammation, CRV431 inhibits fibrotic scarring, which is the primary goal of NASH treatment.
Hepion is currently conducting a Phase 1 clinical trial of CRV431, with plans to initiate a Phase 2 clinical trial in patients with NASH in the second half of 2020.
